2. Search Result
Search Result
Results for "

exatecan derivative

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Fluorescent Dyes

1

Inhibitory Antibodies

3

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13631D
    DXd
    10+ Cited Publications

    exatecan derivative for ADC

    		 Topoisomerase ADC Payload Cancer
    DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
    DXd
  • HY-114233
    MC-GGFG-Exatecan
    5+ Cited Publications

    MC-GGFG-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
    MC-GGFG-Exatecan
  • HY-P3371
    Ifinatamab deruxtecan

    DS-7300a; MABX-9001a; I-DXd

    		 Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
    Ifinatamab deruxtecan
  • HY-13631DS
    DXd-d5

    exatecan-d5 derivative for ADC

    		 Topoisomerase ADC Payload Cancer
    DXd-d5 is a deuterium labeled DXd. DXd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .
    DXd-d5
  • HY-145397
    (4-NH2)-Exatecan

    AZ14170132

    		 ADC Payload Topoisomerase Cancer
    (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .
    (4-NH2)-Exatecan
  • HY-128995AS
    Glycyl-Exatecan-d5 hydrochloride

    Glycyl-DX-8951-d5 hydrochloride; exatecan analog 2-d5 hydrochloride

    		 Isotope-Labeled Compounds ADC Payload Topoisomerase Cancer
    Glycyl-Exatecan-d5 (Glycyl-DX-8951-d5) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research.
    Glycyl-Exatecan-d5 hydrochloride
  • HY-13631J
    (1R,9R)-Exatecan mesylate

    (1R,9R)-DX8951f

    		 Drug Derivative Topoisomerase Apoptosis Cancer
    (1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative and a potent topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1R,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1R,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1R,9R)-Exatecan mesylate is widely used in preclinical studies of multiple cancers including pancreatic cancer, lung cancer, breast cancer, and leukemia . The low-activity isomer of (1R,9R)-Exatecan mesylate is (1S,9R)-Exatecan mesylate (HY-13631I).
    (1R,9R)-Exatecan mesylate
  • HY-42487B
    (R)-Exatecan Intermediate 1

    		Drug Intermediate ADC Payload Topoisomerase Cancer
    (R)-Exatecan Intermediate 1 is a key intermediate in the synthesis of Camptothecin (HY-16560) derivatives, and can be used to prepare Exatecan mesylate (DX8951f) (HY-13631A). (R)-Exatecan Intermediate 1 enables the synthesis of Exatecan, which exhibits low sensitivity to multidrug resistance and has great value in anti-tumor research .
    (R)-Exatecan Intermediate 1
  • HY-176415
    Cys-MC-GGFG-Dxd

    		Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
    Cys-MC-GGFG-Dxd
  • HY-13631I
    (1S,9R)-Exatecan mesylate

    (1S,9R)-DX8951f

    		 Drug Derivative Topoisomerase Apoptosis Cancer
    (1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia .
    The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).
    (1S,9R)-Exatecan mesylate
  • HY-49412
    Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3

    		Drug Intermediate Others
    Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 (compound DC-13-C) is an intermediate in the synthesis of Exatecan (HY-13631) derivatives .
    Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3
  • HY-128995A
    Glycyl-Exatecan TFA

    Glycyl-DX-8951 TFA; exatecan analog 2 TFA

    		 Drug Derivative Cancer
    Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research .
    Glycyl-Exatecan TFA
  • HY-160807
    DBM-GGFG-NH-O-CO-Exatecan

    		Drug-Linker Conjugates for ADC Cancer
    DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .
    DBM-GGFG-NH-O-CO-Exatecan
  • HY-153600
    GGFG-amide-glycol-amide-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    GGFG-amide-glycol-amide-Exatecan (Intermediate 2) is an Exatecan (HY-13631) derivative and can be used in the synthesis of antibody-drug conjugates (ADCs) .
    GGFG-amide-glycol-amide-Exatecan
  • HY-160806
    (5-Cl)-Exatecan

    		ADC Payload Topoisomerase Cancer
    (5-Cl)-Exatecan is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting ROR1-positive cancers. (5-Cl)-Exatecan is applicable for the research of ROR1-positive cancers .
    (5-Cl)-Exatecan
  • HY-156849
    Exatecan-methylacetamide-OH

    		ADC Payload Topoisomerase Cancer
    Exatecan-methylacetamide-OH (compound 6) is a Exatecan derivative with anticancer effects. Exatecan-methylacetamide-OH is an ADC cytotoxin that can be used to synthesize Antibody-Drug Conjugates (ADCs) (CN112125915A; compound 6) .
    Exatecan-methylacetamide-OH
  • HY-153185
    Decyclohexanamine-Exatecan

    		ADC Payload Topoisomerase Cancer
    Decyclohexanamine-Exatecan (compound a) is a Camptothecin derivative, with a structure containing Exatecan (HY-13631), which can be used as a ADC cytotoxin .
    Decyclohexanamine-Exatecan
  • HY-178257
    Fmoc-Val-Lys-PAB-Exatecan

    		ADC Payload Cancer
    Fmoc-Val-Lys-PAB-Exatecan is a derivative of Exatecan (DX-8951) (HY-13631). Fmoc-Val-Lys-PAB-Exatecan can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. Fmoc-Val-Lys-PAB-Exatecan is often combined with CD70 mAb to form ADC drugs for the study of tumors with high CD70 expression .
    Fmoc-Val-Lys-PAB-Exatecan
  • HY-174277
    Antitumor agent-203

    		ADC Payload Topoisomerase Cancer
    Antitumor agent-203 (例7) is a derivative of Exatecan (DX-8951) (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs), as the ADC Cytotoxin .
    Antitumor agent-203
  • HY-145397A
    (R)-(4-NH2)-Exatecan

    (R)-AZ14170132

    		 ADC Payload Topoisomerase Cancer
    (R)-(4-NH2)-Exatecan is the R enantiomer of (4-NH2)-Exatecan (Compound A). (R)-(4-NH2)-Exatecan, a topoisomerase inhibitor, is a derivative of Exatecan. (R)-(4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .
    (R)-(4-NH2)-Exatecan
  • HY-178265
    Exatecan-3-amine

    		ADC Payload Cancer
    Exatecan-3-amine is an effective exatecan derivative. Exatecan-3-amine can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. Exatecan-3-amine is often combined with CLDN6 mAb to form ADC drugs for the study of tumors with high expression of CLDN6 .
    Exatecan-3-amine
  • HY-178315
    Exatecan analog 38

    		Topoisomerase ADC Payload Cancer
    Exatecan analog 38 is a camptothecin derivative with potent topoisomerase I inhibitory activity. Exatecan analog 38 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. Exatecan analog 38 can be used for cancer research .
    Exatecan analog 38
  • HY-160543
    Exatecan-amide-CH2-O-CH2-CH2-OH

    		ADC Payload Topoisomerase Cancer
    Exatecan-amide-CH2-O-CH2-CH2-OH (Compound 4) is a derivative of Exatecan (HY-13631). Exatecan-amide-CH2-O-CH2-CH2-OH can be used for the research of cell proliferative diseases such as cancer .
    Exatecan-amide-CH2-O-CH2-CH2-OH
  • HY-160597
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ol

    		ADC Payload Topoisomerase Cancer
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ol (Compound 79) is an exatecan (HY-13631) derivative that can be used as a payload in drug conjugates. Exatecan-amide-bicyclo[1.1.1]pentan-1-ol has significant inhibitory activity against a variety of tumor cell lines .
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ol
  • HY-145397S
    (4-NH2)-Exatecan-d5

    AZ14170132-d5

    		 Isotope-Labeled Compounds Topoisomerase ADC Payload Cancer
    (4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan . (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .
    (4-NH2)-Exatecan-d5
  • HY-13631Q
    (1R,9R)-rel-Exatecan

    		Drug Derivative Others
    (1R,9R)-rel-Exatecan is a L-Dp derivative. (1R,9R)-rel-Exatecan can be produced by the cleavage of L-Dp (a drug-linker) under cellular conditions .
    (1R,9R)-rel-Exatecan
  • HY-185101
    MC-AcLys-GDEVD-PABC-Exatecan

    		Drug-Linker Conjugates for ADC Cancer
    MC-AcLys-GDEVD-PABC-Exatecan (MC-AcLys-GDEVD-PABC-DX8951) is a agent-linker conjugate for ADC. MC-AcLys-GDEVD-PABC-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with a novel caspase-3 cleavable peptide linker MC-AcLys-GDEVD-PABC linker. MC-AcLys-GDEVD-PABC-Exatecan can be used to prepare DX8951 antibody conjugate (ADC), and it exhibites significant bystander effect mediated by the caspase-3-triggered extracellular cleavage of the linker, enhancing payload release into the tumor microenvironment.
    MC-AcLys-GDEVD-PABC-Exatecan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: